Inhibitors targeting discoidin domain receptor 1 (DDR1), BAY-826 and DDR-IN-1 are promising hits as DDR1 inhibition has potential in cancer therapy (Elkamhawy et al., 2021; Berestjuk et al., 2022). This evidence concerns the gene DDR1 and cancer.